Efficacy of Piroxicam Mesotherapy in Treatment of Knee Osteoarthritis: A Randomized Clinical Trial

Table 5

WOMAC score in both groups during the follow-up.

	Mesotherapy group	Oral therapy group	value (within groups)	value (between groups)
WOMAC^a, mean ± SD^b
Pain			Mesotherapy group: 0.001; Oral therapy group: 0.04
Baseline	16.00 ± 3.49	14.96 ± 3.33		0.13
2^nd week	11.13 ± 2.89	13.26 ± 3.01		0.04
4^th week	8.04 ± 2.40	12.64 ± 2.98		0.01
8^th week	7.55 ± 2.40	11.38 ± 2.90		0.01
Stiffness			Mesotherapy group: 0.001; Oral therapy group: 0.06
Baseline	4.03 ± 1.94	3.97 ± 1.34		0.66
2^nd week	3.07 ± 1.23	3.78 ± 1.25		0.03
4^th week	2.36 ± 0.61	3.68 ± 1.15		0.01
8^th week	2.33 ± 0.65	3.36 ± 1.05		0.02
Function			Mesotherapy group: 0.001; Oral therapy group: 0.03
Baseline	33.35 ± 9.85	31.51 ± 9.75		0.12
2^nd week	18.32 ± 8.19	24.68 ± 8.11		0.04
4^th week	9.45 ± 6.48	16.45 ± 8.09		0.03
8^th week	8.74 ± 7.07	12.63 ± 7.78		0.04
Total score			Mesotherapy group: 0.001; Oral therapy group: 0.04
Baseline	53.38 ± 14.41	50.44 ± 14.14		0.17
2^nd week	32.52 ± 10.11	41.72 ± 10.76		0.02
4^th week	19.85 ± 6.78	32.77 ± 10.34		0.001
8^th week	18.62 ± 6.11	27.37 ± 9.55		0.02

^aWOMAC, Western Ontario and McMaster Universities Arthritis Index; ^bSD, standard deviation.